Athernal Bio

Athernal Bio is a Cambridge-based biotechnology company pioneering cancer interception by developing targeted immunotherapies to treat blood cancer precursor conditions before they become established. Founded in 2024 and based at the Babraham Research Campus, the company focuses on high-risk clonal haematopoiesis (CH), a widespread precursor condition that significantly increases the risk of acute myeloid leukemia (AML) and other hematological malignancies. Athernal Bio's platform is designed to train the immune system to detect and eliminate mutated hematopoietic stem cells, preventing progression to active cancer. The company's pipeline includes three preclinical programs targeting rare inherited blood disorders, treatment-induced clonal haematopoiesis in cancer survivors, and age-related CH in older adults.